{"componentChunkName":"component---node-modules-gatsby-theme-mdx-deck-src-templates-deck-js","path":"/acute-mesenteric-ischemia/tace/print","result":{"data":{"deck":{"id":"2484f9e2-8518-5997-816a-43c2dd088928","body":"function _extends() { _extends = Object.assign || function (target) { for (var i = 1; i < arguments.length; i++) { var source = arguments[i]; for (var key in source) { if (Object.prototype.hasOwnProperty.call(source, key)) { target[key] = source[key]; } } } return target; }; return _extends.apply(this, arguments); }\n\nfunction _objectWithoutProperties(source, excluded) { if (source == null) return {}; var target = _objectWithoutPropertiesLoose(source, excluded); var key, i; if (Object.getOwnPropertySymbols) { var sourceSymbolKeys = Object.getOwnPropertySymbols(source); for (i = 0; i < sourceSymbolKeys.length; i++) { key = sourceSymbolKeys[i]; if (excluded.indexOf(key) >= 0) continue; if (!Object.prototype.propertyIsEnumerable.call(source, key)) continue; target[key] = source[key]; } } return target; }\n\nfunction _objectWithoutPropertiesLoose(source, excluded) { if (source == null) return {}; var target = {}; var sourceKeys = Object.keys(source); var key, i; for (i = 0; i < sourceKeys.length; i++) { key = sourceKeys[i]; if (excluded.indexOf(key) >= 0) continue; target[key] = source[key]; } return target; }\n\n/* @jsx mdx */\nvar theme = customTheme;\nvar _frontmatter = {};\n\nvar makeShortcode = function makeShortcode(name) {\n  return function MDXDefaultShortcode(props) {\n    console.warn(\"Component \" + name + \" was not imported, exported, or provided by MDXProvider as global scope\");\n    return mdx(\"div\", props);\n  };\n};\n\nvar Notes = makeShortcode(\"Notes\");\nvar layoutProps = {\n  theme: theme,\n  _frontmatter: _frontmatter\n};\nvar MDXLayout = \"wrapper\";\nreturn function MDXContent(_ref) {\n  var components = _ref.components,\n      props = _objectWithoutProperties(_ref, [\"components\"]);\n\n  return mdx(MDXLayout, _extends({}, layoutProps, props, {\n    components: components,\n    mdxType: \"MDXLayout\"\n  }), mdx(Slide, {\n    mdxType: \"Slide\"\n  }, mdx(Flex, {\n    mdxType: \"Flex\"\n  }, mdx(\"div\", null, mdx(\"h1\", null, \"Transarterial chemoembolization for hepatocellular carcinoma\"), mdx(\"p\", null, \"Ianto Lin Xi, MS4\")), mdx(\"img\", {\n    src: tace\n  })), mdx(Super, {\n    mdxType: \"Super\"\n  }, \"1\")), mdx(Foot, {\n    mdxType: \"Foot\"\n  }), mdx(\"hr\", null), mdx(Slide, {\n    mdxType: \"Slide\"\n  }, mdx(\"h2\", null, \"Hepatocellular carcinoma \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"1\")), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Dominant primary liver cancer\")), mdx(\"h3\", null, \"Epidemiology \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"2,3,4\")), mdx(\"div\", null, mdx(\"img\", {\n    src: hcctrend\n  }), mdx(\"div\", null, \"Primary liver cancer incidence rate per 100,000 in North and South American countries\")), mdx(\"h3\", null, \"Risk factors \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"3, 4\")), mdx(\"img\", {\n    src: hcccauses\n  })), mdx(Foot, {\n    mdxType: \"Foot\"\n  }), mdx(Notes, {\n    mdxType: \"Notes\"\n  }, mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"epidemiology \", \"[@siegel2020cancer, @monto2001epidemiology, @valery2018projections]\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"6th most frequently diagnosed cancer\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"incidence increasing by 2-3 percent anuually from 2007 through 2016\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"mortality increasing by 0.6 percent between 2013 and 2017\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"second most lethal cancer after pancreatic cancer\"))), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"risk factors\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"male\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"cirrhosis (up to 1/3 of patients with cirrhosis will develop HCC) \", \"[@ioannou2007incidence]\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"chronic viral hepatitis infection\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"alcohol\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"NAFLD/NASH\"))), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"ethnicity: asian pacific islander, black, native american > caucasians\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"environmental toxins: aflatoxin\"))))), mdx(\"hr\", null), mdx(Slide, {\n    mdxType: \"Slide\"\n  }, mdx(\"h2\", null, \"Hepatocellular carcinoma\"), mdx(\"h3\", null, \"Screening \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"6, 7\")), mdx(\"img\", {\n    src: surgroups\n  }), mdx(\"h3\", null, \"Treatment \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"8, 9, 10\")), mdx(\"a\", {\n    href: treatmentpathway\n  }, mdx(\"img\", {\n    src: treatmentpathway\n  }))), mdx(Foot, {\n    mdxType: \"Foot\"\n  }), mdx(Notes, {\n    mdxType: \"Notes\"\n  }, mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"who should be screened for HCC \", \"[@kanwal2019surveillance]\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"cirrhosis: Child Pugh class A/B and C if waitlisted for transplant\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"chronic hep B: large randomized trial \", \"[@zhang2004randomized]\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"asian, african descent, family hx of HCC\"))), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"screening: ultrasound and AFP every six months: look for lesions greater than 1cm => further imaging with CT or MR w/ contrast => potentially needs biopsy\"))), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"brief overview of treatment pathway and modalities \", \"[@hatzaras2014treatment;@xu2019risk]\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"treatment of \", mdx(\"strong\", {\n    parentName: \"li\"\n  }, \"underlying liver disease\"), \", immunizations\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"in general, referrals will be processed by our tumor board, a multidiscipinary team of onc, surgeons, rad onc, and IR: TACE is only one treatment modality of many and this indiscipinary board helps specialists avoid tunnel vision\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"nonresectable: stages IIIB, IVa, IVb to be incurable by resection\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"extrahepatic or nodal disease spread\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"major portal or hepatic vein invasion\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"perforation of visceral peritoneum\"))), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"anatomical constraints of intrahepatic tumor\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"poor underlying liver function (Child Pugh, MELD score)\"))))), mdx(\"hr\", null), mdx(Slide, {\n    mdxType: \"Slide\"\n  }, mdx(\"h2\", null, \"Transarterial chemoembolization \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"1, 11\")), mdx(\"h3\", null, \"Theory and liver physiology\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Tumors receive 90% of their blood supply from the arterial supply\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Hepatic tissue can survive off portal flow alone\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Lipiodol is selectively taken up and retained in HCC and hypervascular liver tumors\")), mdx(\"h3\", null, \"Steps in broad strokes\"), mdx(\"img\", {\n    src: tacediagram\n  }), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"catheter selection of a segmental or subsegmental vessel that feeds tumor\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"injection of lipiodol and chemotherapeutic agent (antracycline) with live visualization of therapeutic agents\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"injection of embolization agents\"))), mdx(Foot, {\n    mdxType: \"Foot\"\n  }), mdx(Notes, {\n    mdxType: \"Notes\"\n  }, \"- description of the technique - uses an emulsion of lipiodol with an anthracycline chemotherapeutic drug, followed by solid embolic material - **super selective embolization** is recommended: because it has demonstrated better results than lobar or whole liver TACE. Selective embolization demonstrated improved survival (hazard ratio 0.68; 95% CI 0.48\\u20130.97; p = 0.033) in a multivariate analysis of 815 patients receiving TACE for HCC [@yamakado2012hepatic] - A major advantage of Lipiodol TACE is the ability to control the delivery of the treatment by **continuous visualization of the therapeutic agents due to radio-opacity of Lipiodol.** Real time visualiztion of targeting and distribution of chemotherapy. - at least two sequential TACEs are performed typically - additional sessions are indicated for new progression after response to previous treatment, but should be stopped in patients presenting with untreatable progression (absence of tumor response in treated territories after two embolizations or impossibility to reach tumor feeders of some territories) or clinical deterioration - sessions are spaced 2-8 weeks apart - angiography slides - indications - intermediate HCC - more advanced HCC with adequately preserved hepatic function - Lipiodol TACE remains the current standard of care in international guidelines for large or multinodular tumor isolated to the liver with preserved liver function and absence of portal vein invasion - Treatment with TACE should be discontinued in patients presenting with untreatable progression that is defined by the absence of tumor response in the treated territories after two embolizations or the impossibility to reach tumor feeders of some territories. - other indications - liver-dominant neuroendocrine tumors - contraindications - portal vein thrombosis: blood supply to liver is compromised and may result in hepatic infarction and acute hepatic failure - may not be an absolute contraindication, relative only - poor hepatic function - renal insufficiency? - marked arterioportal shunting\"), mdx(\"hr\", null), mdx(Slide, {\n    mdxType: \"Slide\"\n  }, mdx(\"h2\", null, \"Summary\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"HCC is a\")), mdx(\"h3\", null, \"Prognosis\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Tumors often survive TACE therapy and require additional treatment\", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"13\"))), mdx(\"p\", null, mdx(\"img\", {\n    src: tacepaper1\n  }), mdx(\"img\", {\n    src: tacepaper1f3\n  })), mdx(\"p\", null, mdx(\"img\", {\n    src: tacepaper2\n  }), mdx(\"img\", {\n    src: tacepaper2f2\n  })), mdx(\"p\", null, mdx(\"img\", {\n    src: tacepaper3\n  }), mdx(\"img\", {\n    src: tacepaper3f1\n  })), mdx(\"h3\", null, \"Complications \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"17\")), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Post embolization syndrome (90%): right upper quadrant abdominal pain, fever, malaise, and/or nausea and vomiting\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Liver abscesses (2%)\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Arterial injury (<1%): pseudoanerusym, dissection, hematoma, AV fistula\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Nontarget embolization (<1%): targetting of gallbladder, gastric ulcers, duodenal ulcers, acute pancreatitis\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Biliary ischemia and bilomas (<1%)\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Tumor rupture (<1%)\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Pulmonary embolism (<1%)\")), mdx(\"h3\", null, \"Example \", mdx(Super, {\n    mdxType: \"Super\"\n  }, \"1\")), mdx(\"img\", {\n    src: beforeafter\n  })), mdx(Foot, {\n    mdxType: \"Foot\"\n  }), mdx(Notes, {\n    mdxType: \"Notes\"\n  }, mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Results\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"two randomized studies which used either doxorubicin \", \"[@llovet2002arterial]\", \" or cis-platinum \", \"[@lo2002randomized]\", \" mixed with Lipiodol, followed by administration of an embolic agent. To date these studies represent the only controlled trials for intra-arterial therapies for HCC demonstrating the superiority of Lipiodol TACE to best supportive care.\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"llovet2002arterial: Lancet\"))), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"In a prospective \", mdx(\"strong\", {\n    parentName: \"li\"\n  }, \"nonrandomized\"), \" study, 164 HCC patients with segmental or subsegmental portal vein thrombosis were treated with TACE or conservative care according to the patient\\u2019s preference after counseling from a tumor board. The 12- and 24-month overall survival rates for the TACE and conservative groups were 30.9% and 9.2%, vs. 3.8% and 0% (p < 0.001) \", \"[@luo2011transarterial]\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"evidence against: \", mdx(\"a\", _extends({\n    parentName: \"li\"\n  }, {\n    \"href\": \"https://www.uptodate.com/contents/nonsurgical-therapies-for-localized-hepatocellular-carcinoma-transarterial-embolization-radiation-therapy-and-radioembolization/abstract/23,24,30\"\n  }), \"https://www.uptodate.com/contents/nonsurgical-therapies-for-localized-hepatocellular-carcinoma-transarterial-embolization-radiation-therapy-and-radioembolization/abstract/23,24,30\")), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"evidence for: \", mdx(\"a\", _extends({\n    parentName: \"li\"\n  }, {\n    \"href\": \"https://www.uptodate.com/contents/nonsurgical-therapies-for-localized-hepatocellular-carcinoma-transarterial-embolization-radiation-therapy-and-radioembolization/abstract/18,20\"\n  }), \"https://www.uptodate.com/contents/nonsurgical-therapies-for-localized-hepatocellular-carcinoma-transarterial-embolization-radiation-therapy-and-radioembolization/abstract/18,20\")))), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Complications\", mdx(\"ul\", {\n    parentName: \"li\"\n  }, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Post embolization syndrome (90%): right upper quadrant abdominal pain, fever, malaise, and/or nausea and vomiting\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Liver abscesses (2%): predictred by biliary dilatation and biliary enteric continuity resulting in biliary bactrerial contamination\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Arterial injury (<1%): pseudoanerusym, dissection, hematoma, AV fistula\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Nontarget embolization (<1%): targetting of gallbladder, gastric ulcers, duodenal ulcers, acute pancreatitis\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Biliary ischemia and biloma (<1%)\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Tumor rupture (<1%)\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Pulmonary embolism (<1%): AV shunting or PV shunt\"))))), mdx(\"hr\", null), mdx(Slide, {\n    mdxType: \"Slide\"\n  }, mdx(\"h2\", null, \"Summary\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"HCC is the dominant primary liver cancer with increasing incidence and mortality rate\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Cirrhotic patients and certain patients with chronic hepatitis B should be screened for HCC\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, mdx(Emphasis, {\n    mdxType: \"Emphasis\"\n  }, \"The treatment for HCC is best coordinated through multidisciplinary conferences including oncology, surgery, radiation oncology, and interventional radiology\")), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"TACE is a modality of treatment that is often useful in treating HCC\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, mdx(Emphasis, {\n    mdxType: \"Emphasis\"\n  }, \"TACE has been shown to prolong survival in patients with HCC\")), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"The most common complication of TACE is postembolization syndrome\"))), mdx(\"hr\", null), mdx(Slide, {\n    mdxType: \"Slide\"\n  }, mdx(\"h2\", null, \"References\"), mdx(Small, {\n    mdxType: \"Small\"\n  }, mdx(\"p\", null, \"1\", \".\", \" Soulen, M. C. & Baere, T. de. Physics and physiology of\\ntransarterial chemoembolization and drug-eluting beads for liver tumors.\\nin \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Image-guided interventions in oncology\"), \" 29--42 (Springer, 2020).\"), mdx(\"p\", null, \"2\", \".\", \" Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020.\\n\", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"CA: a cancer journal for clinicians\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"70\"), \", 7--30 (2020).\"), mdx(\"p\", null, \"3\", \".\", \" Monto, A. & Wright, T. L. The epidemiology and prevention of\\nhepatocellular carcinoma. in \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Seminars in oncology\"), \" vol. 28 441--449\\n(Elsevier, 2001).\"), mdx(\"p\", null, \"4\", \".\", \" Valery, P. C. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Projections of primary liver cancer to 2030\\nin 30 countries worldwide. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Hepatology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"67\"), \", 600--611 (2018).\"), mdx(\"p\", null, \"5\", \".\", \" Ioannou, G. N. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Incidence and predictors of hepatocellular\\ncarcinoma in patients with cirrhosis. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Clinical gastroenterology and\\nhepatology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"5\"), \", 938--945 (2007).\"), mdx(\"p\", null, \"6\", \".\", \" Kanwal, F. & Singal, A. G. Surveillance for hepatocellular\\ncarcinoma: Current best practice and future direction.\\n\", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Gastroenterology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"157\"), \", 54--64 (2019).\"), mdx(\"p\", null, \"7\", \".\", \" Zhang, B.-H., Yang, B.-H. & Tang, Z.-Y. Randomized controlled trial\\nof screening for hepatocellular carcinoma. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Journal of cancer research\\nand clinical oncology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"130\"), \", 417--422 (2004).\"), mdx(\"p\", null, \"8\", \".\", \" Hatzaras, I., Bischof, D. A., Fahy, B., Cosgrove, D. & Pawlik, T. M.\\nTreatment options and surveillance strategies after therapy for\\nhepatocellular carcinoma. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Annals of surgical oncology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"21\"), \", 758--766\\n(2014).\"), mdx(\"p\", null, \"9\", \".\", \" Xu, X.-F. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Risk factors, patterns, and outcomes of late\\nrecurrence after liver resection for hepatocellular carcinoma: A\\nmulticenter study from china. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"JAMA surgery\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"154\"), \", 209--217 (2019).\"), mdx(\"p\", null, \"10\", \".\", \" Abdalla, E. & Stuart, K. E. Overview of treatment approaches for\\nhepatocellular carcinoma. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"UpToDate\"), \" (2013).\"), mdx(\"p\", null, \"11\", \".\", \" West, H. J. & Jin, J. O. Transarterial chemoembolization. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"JAMA\\noncology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"1\"), \", 1178--1178 (2015).\"), mdx(\"p\", null, \"12\", \".\", \" Yamakado, K. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Hepatic arterial embolization for\\nunresectable hepatocellular carcinomas: Do technical factors affect\\nprognosis? \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Japanese journal of radiology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"30\"), \", 560--566 (2012).\"), mdx(\"p\", null, \"13\", \".\", \" Perkons, N. R. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Hyperpolarized metabolic imaging detects\\nlatent hepatocellular carcinoma domains surviving locoregional therapy.\\n\", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Hepatology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"72\"), \", 140--154 (2020).\"), mdx(\"p\", null, \"14\", \".\", \" Llovet, J. M. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Arterial embolisation or chemoembolisation\\nversus symptomatic treatment in patients with unresectable\\nhepatocellular carcinoma: A randomised controlled trial. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"The Lancet\"), \"\\n\", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"359\"), \", 1734--1739 (2002).\"), mdx(\"p\", null, \"15\", \".\", \" Lo, C.-M. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Randomized controlled trial of transarterial\\nlipiodol chemoembolization for unresectable hepatocellular carcinoma.\\n\", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Hepatology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"35\"), \", 1164--1171 (2002).\"), mdx(\"p\", null, \"16\", \".\", \" Luo, J. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"et al.\"), \" Transarterial chemoembolization for unresectable\\nhepatocellular carcinoma with portal vein tumor thrombosis: A\\nprospective comparative study. \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Annals of surgical oncology\"), \" \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"18\"), \",\\n413--420 (2011).\"), mdx(\"p\", null, \"17\", \".\", \" Spolverato, G., Deipolyi, A. R. & D'Angelica, M. Complications of\\nintra-arterial regional liver therapy. in \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"Cancer regional therapy\"), \"\\n341--353 (Springer, 2020).\"))), mdx(Foot, {\n    mdxType: \"Foot\"\n  }));\n}\n;\nMDXContent.isMDXComponent = true;"}},"pageContext":{"isCreatedByStatefulCreatePages":false,"id":"2484f9e2-8518-5997-816a-43c2dd088928","slug":"/acute-mesenteric-ischemia/tace","title":"Transarterial chemoembolization for hepatocellular carcinoma"}}}